Literature DB >> 28223370

LIM-Only Protein FHL2 Is a Negative Regulator of Transforming Growth Factor β1 Expression.

Jennifer Dahan1,2, Florence Levillayer1,2, Tian Xia2, Yann Nouët1, Catherine Werts3, Martine Fanton d'Andon3, Minou Adib-Conquy4, Anne-Marie Cassard-Doulcier5, Varun Khanna6, Ju Chen7, Thierry Tordjmann8, Marie-Annick Buendia1, Grégory Jouvion9, Yu Wei10,2.   

Abstract

Transforming growth factor β1 (TGF-β1) is a master cytokine in many biological processes, including tissue homeostasis, epithelial-to-mesenchymal transition, and wound repair. Here, we report that four and a half LIM-only protein 2 (FHL2) is a critical regulator of TGF-β1 expression. Devoid of a DNA-binding domain, FHL2 is a transcriptional cofactor that plays the role of coactivator or corepressor, depending on the cell and promoter contexts. We detected association of FHL2 with the TGF-β1 promoter, which showed higher activity in Fhl2-/- cells than in wild-type (WT) cells in a reporter assay. Overexpression of FHL2 abrogates the activation of the TGF-β1 promoter, whereas the upregulation of TGF-β1 gene transcription correlates with reduced occupancy of FHL2 on the promoter. Moreover, ablation of FHL2 facilitates recruitment of RNA polymerase II on the TGF-β1 promoter, suggesting that FHL2 may be involved in chromatin remodeling in the control of TGF-β1 gene transcription. Enhanced expression of TGF-β1 mRNA and cytokine was evidenced in the livers of Fhl2-/- mice. We tested the in vivo impact of Fhl2 loss on hepatic fibrogenesis that involves TGF-β1 activation. Fhl2-/- mice developed more severe fibrosis than their WT counterparts. These results demonstrate the repressive function of FHL2 on TGF-β1 expression and contribute to the understanding of the TGF-β-mediated fibrogenic response.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  FHL2; TGF-β1; fibrosis; transcription regulation

Mesh:

Substances:

Year:  2017        PMID: 28223370      PMCID: PMC5477553          DOI: 10.1128/MCB.00636-16

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  37 in total

1.  PROMO: detection of known transcription regulatory elements using species-tailored searches.

Authors:  Xavier Messeguer; Ruth Escudero; Domènec Farré; Oscar Núñez; Javier Martínez; M Mar Albà
Journal:  Bioinformatics       Date:  2002-02       Impact factor: 6.937

2.  The LIM-only proteins FHL2 and FHL3 interact with alpha- and beta-subunits of the muscle alpha7beta1 integrin receptor.

Authors:  Thomas Samson; Neil Smyth; Stefanie Janetzky; Olaf Wendler; Judith M Müller; Roland Schüle; Helga von der Mark; Klaus von der Mark; Viktor Wixler
Journal:  J Biol Chem       Date:  2004-04-26       Impact factor: 5.157

3.  Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence.

Authors:  Philip Kahl; Lucia Gullotti; Lukas Carl Heukamp; Susanne Wolf; Nicolaus Friedrichs; Roland Vorreuther; Gerold Solleder; Patrick J Bastian; Jörg Ellinger; Eric Metzger; Roland Schüle; Reinhard Buettner
Journal:  Cancer Res       Date:  2006-12-01       Impact factor: 12.701

4.  TLR4 enhances TGF-beta signaling and hepatic fibrosis.

Authors:  Ekihiro Seki; Samuele De Minicis; Christoph H Osterreicher; Johannes Kluwe; Yosuke Osawa; David A Brenner; Robert F Schwabe
Journal:  Nat Med       Date:  2007-10-21       Impact factor: 53.440

5.  LIM-only protein FHL2 activates NF-κB signaling in the control of liver regeneration and hepatocarcinogenesis.

Authors:  Jennifer Dahan; Yann Nouët; Grégory Jouvion; Florence Levillayer; Minou Adib-Conquy; Anne-Marie Cassard-Doulcier; Ali Tebbi; Fany Blanc; Lauriane Remy; Ju Chen; Stefano Cairo; Catherine Werts; Mustapha Si-Tahar; Thierry Tordjmann; Marie-Annick Buendia; Yu Wei
Journal:  Mol Cell Biol       Date:  2013-06-17       Impact factor: 4.272

6.  Human four-and-a-half LIM family members suppress tumor cell growth through a TGF-beta-like signaling pathway.

Authors:  Lihua Ding; Zhaoyun Wang; Jinghua Yan; Xiao Yang; Aijun Liu; Weiyi Qiu; Jianhua Zhu; Juqiang Han; Hao Zhang; Jing Lin; Long Cheng; Xi Qin; Chang Niu; Bin Yuan; Xiaohui Wang; Cui Zhu; Yan Zhou; Jiezhi Li; Haifeng Song; Cuifen Huang; Qinong Ye
Journal:  J Clin Invest       Date:  2009-01-12       Impact factor: 14.808

7.  Characterization of the mouse transforming growth factor-beta 1 promoter and activation by the Ha-ras oncogene.

Authors:  A G Geiser; S J Kim; A B Roberts; M B Sporn
Journal:  Mol Cell Biol       Date:  1991-01       Impact factor: 4.272

8.  Transforming growth factor beta 1 positively regulates its own expression in normal and transformed cells.

Authors:  E Van Obberghen-Schilling; N S Roche; K C Flanders; M B Sporn; A B Roberts
Journal:  J Biol Chem       Date:  1988-06-05       Impact factor: 5.157

9.  SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7.

Authors:  Gareth J Inman; Francisco J Nicolás; James F Callahan; John D Harling; Laramie M Gaster; Alastair D Reith; Nicholas J Laping; Caroline S Hill
Journal:  Mol Pharmacol       Date:  2002-07       Impact factor: 4.436

10.  The LIM-only protein FHL2 interacts with beta-catenin and promotes differentiation of mouse myoblasts.

Authors:  Bernd Martin; Richard Schneider; Stefanie Janetzky; Zoe Waibler; Petra Pandur; Michael Kühl; Jürgen Behrens; Klaus von der Mark; Anna Starzinski-Powitz; Viktor Wixler
Journal:  J Cell Biol       Date:  2002-10-07       Impact factor: 10.539

View more
  9 in total

1.  PARP12 (ARTD12) suppresses hepatocellular carcinoma metastasis through interacting with FHL2 and regulating its stability.

Authors:  Changjuan Shao; Yangyang Qiu; Juan Liu; Huan Feng; Suqin Shen; Hexige Saiyin; Wenbo Yu; Youheng Wei; Long Yu; Wei Su; Jiaxue Wu
Journal:  Cell Death Dis       Date:  2018-08-28       Impact factor: 8.469

2.  Pirfenidone attenuates lung fibrotic fibroblast responses to transforming growth factor-β1.

Authors:  Jin Jin; Shinsaku Togo; Kotaro Kadoya; Miniwan Tulafu; Yukiko Namba; Moe Iwai; Junko Watanabe; Kumi Nagahama; Takahiro Okabe; Moulid Hidayat; Yuzo Kodama; Hideya Kitamura; Takashi Ogura; Norikazu Kitamura; Kazuho Ikeo; Shinichi Sasaki; Shigeru Tominaga; Kazuhisa Takahashi
Journal:  Respir Res       Date:  2019-06-11

3.  Transcriptomic and ChIP-sequence interrogation of EGFR signaling in HER2+ breast cancer cells reveals a dynamic chromatin landscape and S100 genes as targets.

Authors:  Miguel Nava; Pranabananda Dutta; Nathan R Zemke; Robin Farias-Eisner; Jaydutt V Vadgama; Yanyuan Wu
Journal:  BMC Med Genomics       Date:  2019-02-08       Impact factor: 3.063

4.  Integrated nomogram based on five stage-related genes and TNM stage to predict 1-year recurrence in hepatocellular carcinoma.

Authors:  Haohan Liu; Yongcong Yan; Ruibing Chen; Mengdi Zhu; Jianhong Lin; Chuanchao He; Bingchao Shi; Kai Wen; Kai Mao; Zhiyu Xiao
Journal:  Cancer Cell Int       Date:  2020-04-29       Impact factor: 5.722

5.  FHL3 promotes pancreatic cancer invasion and metastasis through preventing the ubiquitination degradation of EMT associated transcription factors.

Authors:  Pengping Li; Guodong Cao; Yuefeng Zhang; Jingbo Shi; Kailun Cai; Lei Zhen; Xiaobo He; Yizhao Zhou; Yongzhou Li; Yi Zhu; Maoming Xiong; Yulian Wu
Journal:  Aging (Albany NY)       Date:  2020-01-13       Impact factor: 5.682

Review 6.  Research Advances in the Role of the Poly ADP Ribose Polymerase Family in Cancer.

Authors:  Huanhuan Sha; Yujie Gan; Renrui Zou; Jianzhong Wu; Jifeng Feng
Journal:  Front Oncol       Date:  2021-12-16       Impact factor: 6.244

7.  QiShenYiQi Pill Ameliorates Cardiac Fibrosis After Pressure Overload-Induced Cardiac Hypertrophy by Regulating FHL2 and the Macrophage RP S19/TGF-β1 Signaling Pathway.

Authors:  Gulinigaer Anwaier; Ting-Ting Xie; Chun-Shui Pan; An-Qing Li; Li Yan; Di Wang; Fan-Kai Chen; Ding-Zhou Weng; Kai Sun; Xin Chang; Jing-Yu Fan; Jing-Yan Han; Jian Liu
Journal:  Front Pharmacol       Date:  2022-07-13       Impact factor: 5.988

8.  Deletion of the FHL2 gene attenuates intima-media thickening in a partially ligated carotid artery ligated mouse model.

Authors:  Chi-Yu Chen; Hsiao-Ya Tsai; Shih-Hung Tsai; Pao-Hsien Chu; Po-Hsun Huang; Jaw-Wen Chen; Shing-Jong Lin
Journal:  J Cell Mol Med       Date:  2019-11-12       Impact factor: 5.310

9.  Four-And-A-Half LIM-Domain Protein 2 (FHL2) Deficiency Aggravates Cholestatic Liver Injury.

Authors:  Judith Sommer; Christoph Dorn; Erwin Gäbele; Frauke Bataille; Kim Freese; Tatjana Seitz; Wolfgang E Thasler; Reinhard Büttner; Ralf Weiskirchen; Anja Bosserhoff; Claus Hellerbrand
Journal:  Cells       Date:  2020-01-19       Impact factor: 6.600

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.